Green Cross Corp (006280) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.094x

Based on the latest financial reports, Green Cross Corp (006280) has a cash flow conversion efficiency ratio of 0.094x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩139.65 Billion ≈ $94.64 Million USD) by net assets (₩1.49 Trillion ≈ $1.01 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Green Cross Corp - Cash Flow Conversion Efficiency Trend (2004–2024)

This chart illustrates how Green Cross Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 006280 current and long-term liabilities for a breakdown of total debt and financial obligations.

Green Cross Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Green Cross Corp ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Elsight Ltd
AU:ELS
0.272x
Anhui Xinlong Electrical Co Ltd
SHE:002298
0.030x
BioPharma Credit PLC
LSE:BPCR
0.029x
Huizhou China Eagle Electronic Technology Co Ltd
SHE:002579
0.090x
Corbion N.V.
F:CSU
0.038x
Anhui Expressway Company Limited
F:HU7
0.030x
Bank Artos Indonesia Tbk PT
JK:ARTO
0.155x
Baota Industry Co Ltd
SHE:000595
0.311x

Annual Cash Flow Conversion Efficiency for Green Cross Corp (2004–2024)

The table below shows the annual cash flow conversion efficiency of Green Cross Corp from 2004 to 2024. For the full company profile with market capitalisation and key ratios, see Green Cross Corp (006280) total market value.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩1.48 Trillion
≈ $1.00 Billion
₩-53.46 Billion
≈ $-36.23 Million
-0.036x -915.64%
2023-12-31 ₩1.54 Trillion
≈ $1.04 Billion
₩-5.47 Billion
≈ $-3.71 Million
-0.004x -104.67%
2022-12-31 ₩1.57 Trillion
≈ $1.06 Billion
₩119.15 Billion
≈ $80.75 Million
0.076x -9.46%
2021-12-31 ₩1.50 Trillion
≈ $1.02 Billion
₩125.98 Billion
≈ $85.37 Million
0.084x +196.39%
2020-12-31 ₩1.27 Trillion
≈ $860.19 Million
₩35.97 Billion
≈ $24.38 Million
0.028x -16.71%
2019-12-31 ₩1.18 Trillion
≈ $802.43 Million
₩40.29 Billion
≈ $27.30 Million
0.034x +165.94%
2018-12-31 ₩1.13 Trillion
≈ $763.21 Million
₩14.41 Billion
≈ $9.77 Million
0.013x -75.49%
2017-12-31 ₩1.11 Trillion
≈ $751.36 Million
₩57.88 Billion
≈ $39.22 Million
0.052x +3273.10%
2016-12-31 ₩1.06 Trillion
≈ $717.68 Million
₩-1.74 Billion
≈ $-1.18 Million
-0.002x -103.63%
2015-12-31 ₩997.70 Billion
≈ $676.13 Million
₩45.24 Billion
≈ $30.66 Million
0.045x -26.45%
2014-12-31 ₩920.63 Billion
≈ $623.90 Million
₩56.76 Billion
≈ $38.47 Million
0.062x +74.32%
2013-12-31 ₩839.41 Billion
≈ $568.86 Million
₩29.69 Billion
≈ $20.12 Million
0.035x -52.25%
2012-12-31 ₩685.23 Billion
≈ $464.37 Million
₩50.76 Billion
≈ $34.40 Million
0.074x -14.89%
2011-12-31 ₩630.28 Billion
≈ $427.13 Million
₩54.86 Billion
≈ $37.17 Million
0.087x -44.13%
2010-12-31 ₩542.23 Billion
≈ $367.46 Million
₩84.47 Billion
≈ $57.25 Million
0.156x +6.04%
2006-12-31 ₩185.98 Billion
≈ $126.03 Million
₩27.32 Billion
≈ $18.52 Million
0.147x -8.02%
2005-12-31 ₩145.70 Billion
≈ $98.74 Million
₩23.27 Billion
≈ $15.77 Million
0.160x +6.53%
2004-12-31 ₩108.95 Billion
≈ $73.83 Million
₩16.34 Billion
≈ $11.07 Million
0.150x --

About Green Cross Corp

KO:006280 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$1.06 Billion
₩1.56 Trillion KRW
Market Cap Rank
#8850 Global
#249 in Korea
Share Price
₩137100.00
Change (1 day)
-1.51%
52-Week Range
₩118100.00 - ₩180300.00
All Time High
₩493171.17
About

GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-… Read more